AANS Online Scientific Sessions: Tumor-Local Combination Therapy of Poly-ADP-Ribose-Polymerase-Inhibitor Olaparib and Temozolomide-Etoposide From a Biodegradable Paste Potentiates Radiotherapy and Prolongs Survival

Local Combination Therapy of Poly-ADP-Ribose-Polymerase-Inhibitor Olaparib and Temozolomide-Etoposide From a Biodegradable Paste Potentiates Radiotherapy and Prolongs Survival

Video Transcription

Video Summary

In this video, Riccardo Serra, a postdoctoral fellow at Johns Hopkins, discusses the local delivery of a biodegradable thermosensitive base loaded with olaparib to improve radiotherapy and survival in glioblastoma (GBM). He highlights the limitations of current approaches, including the rigid structure of wafer discs and limited drug choices. The study aims to develop new tools for drug delivery, expand drug options, and enhance the effects of radiation therapy. Serra presents the methods used in the study, including in vitro and in vivo experiments, and shares the results, which show increased apoptosis, PARP expression, and DNA damage in treated cells. In the rodent model of gliosarcoma, combination therapy with olaparib, TMZ, and etoposide significantly improved survival compared to controls. Serra also acknowledges the study's limitations and discusses future plans, such as investigating other chemotherapeutic agents and conducting safety and efficacy studies in human GBM patients. He expresses gratitude to his colleagues and collaborators.

Asset Subtitle

Riccardo Serra

Keywords

local delivery

biodegradable base

olaparib

radiotherapy

glioblastoma